Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myovant Sciences Ltd (NY: MYOV )

10.32 -0.17 (-1.62%)
Official Closing Price Updated: 7:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 396,484
Open 10.42
Bid (Size) 9.400 (2)
Ask (Size) 10.30 (1)
Prev. Close 10.49
Today's Range 10.06 - 10.50
52wk Range 7.670 - 27.43
Shares Outstanding 92,077,860
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
Urovant Sciences' interim results from a Phase 2a trial of URO-902 gene therapy were presented at the annual meeting of the American Urological Association (AUA2022). Urovant is a wholly-owned... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga

Performance

YTD
-37.07%
-37.07%
1 Month
+10.02%
+10.02%
3 Month
-15.62%
-15.62%
6 Month
-46.56%
-46.56%
1 Year
-55.23%
-55.23%

More News

Read More
77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Myovant Sciences: Q4 Earnings Insights
Via Benzinga
103 Biggest Movers From Yesterday
Via Benzinga
Myovant, Accord Healthcare Ink Relugolix Distribution Pact For Europe In Prostate Cancer
Via Benzinga
Myovant Sciences' Relugolix For Hormone-Sensitive Prostate Cancer Approved In Europe
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Earnings Preview: Myovant Sciences
Via Benzinga
U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months
Via Benzinga
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow, Nasdaq Up Triple Digits as Wall Street Bets on Inflation's Top
Via Talk Markets
Myovant Sciences Collapses As FDA Holdup Snags Its Blockbuster Potential
Via Investor's Business Daily
What's Going On With Myovant Sciences Stock Today?
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Via Benzinga
Urovant Reports Publication of New Efficacy, Safety Data On Gemtesa For Overactive Bladder
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Bear Market Bets In Biotech
Via Talk Markets
Myovant Sciences's Return on Invested Capital Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.